Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

• Main Authors: Huynh, H, Ngo, V.C, Fargnoli, J, Ayers, M, Khee, C.S, Heng, N.K, Choon, H.T, Hock, S.O, Chung, A, Chow, P, Pollock, P, Byron, S, Tran, E
• 其他作者: MEDICINE
• 格式: Article
• 出版: 2020
• 主題: basic fibroblast growth factor; brivanib alaninate; caspase 3; CD31 antigen; fibroblast growth factor receptor 1; Ki 67 antigen; mitogen activated protein kinase 1; mitogen activated protein kinase 3; protein kinase B; vasculotropin; vasculotropin receptor 2; alanine; drug derivative; fibroblast growth factor receptor; triazine derivative; vasculotropin receptor; animal experiment; animal model; animal tissue; antiangiogenic activity; antiangiogenic therapy; antineoplastic activity; apoptosis; article; cancer inhibition; cancer model; cell proliferation; cell strain HepG2; controlled study; down regulation; drug mechanism; drug sensitivity; enzyme inhibition; human; human cell; human tissue; liver cell carcinoma; male; microvasculature; mouse; neovascularization (pathology); nonhuman; priority journal; protein expression; protein phosphorylation; signal transduction; tumor vascularization; tumor xenograft; weight change; animal; cancer transplantation; chemical model; drug antagonism; liver tumor; metabolism; tumor cell line; Alanine; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Male; Mice; Models, Chemical; Neoplasm Transplantation; Neovascularization, Pathologic; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Triazines
• 在線閱讀: https://scholarbank.nus.edu.sg/handle/10635/181019
• 機構: National University of Singapore

10.1158/1078-0432.CCR-08-0509